EMD Millipore Launches RNA Reprogramming Technology
EMD Millipore, the Life Science division of Merck KGaA of Darmstadt, Germany, recently launched Simplicon RNA Reprogramming Technology, which uses synthetic self-replicating RNA to create large numbers of human-induced pluripotent stem cells (iPSCs) using a single transfection step. This efficient reprogramming of somatic cells is accomplished without viral intermediates or host genome integration, offering a more defined and safer system for iPSC generation.
“For stem cell researchers using iPSCs to study disease, differentiation, and regenerative medicine, there’s a real need for a reprogramming method that’s as efficient as virus-based techniques yet as safe as non-viral methods,” said Christophe Couturier, Head of Bioscience, EMD Millipore. “Simplicon technology meets this need, with a single-transfection protocol that’s significantly easier than other approaches.”
The Simplicon RNA Reprogramming Technology uses a single synthetic, polycistronic self-replicating RNA strand engineered to mimic cellular RNA. The RNA strand contains the four reprogramming factors, OCT-4, KLF-4, SOX-2 and GLIS1, and enables the creation of integration- and virus-free iPSCs using only one transfection step. Once the cells are generated, the RNA and reprogramming factors can easily be eliminated from the cell culture medium in a controlled manner.
EMD Millipore launced the Simplicon RNA Reprogramming Technology at the International Society for Stem Cell Research (ISSCR) annual meeting being held June 18-21 in Vancouver, Canada. For more information, please visit www.emdmillipore.com/simplicon.
Total Page Views: 700
